4th June 2019
Professor Peter Schmid, Lead of the Centre for Experimental Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London, attended this year’s ASCO Annual Meeting and today presented updated survival data from the IMpassion130 trial.
Read more5th March 2019
Dr Ranjit Manchanda from Barts Cancer Institute, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts Health NHS Trust, was announced today as one of 13 Fellows to join the NHS […]
Read more19th November 2018
Centrosomal amplification, a particular change that occurs within some cancer cells, has been shown to drive the invasion of neighbouring cancer cells.
Read more22nd October 2018
Research provides new hope for people with an aggressive type of breast cancer.
Read more17th October 2018
Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC).
Read more8th June 2018
Current detection strategies are found to have identified only 2.6% of the BRCA gene mutation carriers in the Greater London population, according to a recent study published in the Journal of Medical genetics. The findings of the study, performed by researchers from the BCI’s Centre for Experimental Cancer Medicine, led by Dr Ranjit Manchanda, suggest that enhanced and new approaches are required to maximise the opportunity for breast and ovarian cancer prevention.
Read more